# AML-Genomic-Subtyping-with-Graphs-Causality

This project explores acute myeloid leukemia (AML) genomic subtypes using a graph-based machine learning approach, inspired by the paper:

â€œMachine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemiaâ€
Blood (2021) https://ashpublications.org/blood/article-abstract/138/19/1885/476049

Instead of using traditional supervised classifiers alone, this project takes a network-driven perspective to understand how mutations co-occur, cluster, and define biological AML subtypes.


ğŸ’¡ Core Idea

AML is not driven by single mutations, but by combinations of cooperating mutations that define distinct disease entities.

This project answers three key questions:

Which mutations tend to appear together in the same patients?

Can we automatically identify mutation communities (subtypes)?

Which mutations show strong positive or negative (exclusive) relationships?


ğŸ“Š Data

Source: Simulated AML mutation matrix derived from TCGA-LAML (Genomic Data Commons, NCI)

Patients: ~3000

Genes analyzed (binary: mutated / not mutated):

NPM1, FLT3-ITD, DNMT3A

RUNX1, ASXL1, SRSF2, U2AF1

TP53, Complex Karyotype

IDH1, IDH2

CEBPA (biallelic)

âš ï¸ Data are simulated for methodological demonstration, not direct clinical inference.


ğŸ”— 1. Co-occurrence Network (Graph-Based View)
What does the graph represent?

Nodes (dots) â†’ Gene mutations

Edges (lines) â†’ Two mutations appear together in many patients

Edge thickness â†’ Number of patients sharing both mutations

Threshold applied â†’ Only draw an edge if >80 patients have both mutations

co_occurrence = aml_df[GENES].T.dot(aml_df[GENES])

This matrix counts how many patients carry both mutation A and mutation B.


Why use a threshold (e.g. >80 patients)?

Small co-occurrence counts can occur by chance

Larger counts are more biologically meaningful

Thresholding reduces noise and improves interpretability

Trade-off: rare but real relationships may be missed â€” this is intentional to focus on dominant AML biology.


2. Automatic Mutation Community Detection

To identify groups of mutations that tend to appear together, we applied modularity-based community detection:

communities = greedy_modularity_communities(G)

Resulting mutation communities:

Module 1
Core AML signaling / epigenetic mutations
(NPM1, FLT3-ITD, DNMT3A, IDH2, RUNX1, splicing genes)

Module 2
Adverse-risk AML
(TP53, Complex Karyotype, ASXL1)

Module 3
Isolated metabolic subtype
(IDH1)

These communities emerge automatically, without predefined labels â€” showing that graph structure alone recovers known AML subtypes.


ğŸ§  3. Raw Co-occurrence Counts (Transparency)

To maintain interpretability, the project also prints:

The full co-occurrence matrix

A ranked table of significant mutation pairs

Example:

Gene 1	Gene 2	Patients
NPM1	DNMT3A	472
NPM1	FLT3-ITD	458
TP53	Complex Karyotype	367
RUNX1	SRSF2	385

These numbers align strongly with established AML biology.


ğŸ¨ Visualization (What You See in the Figure)
Node Colors (Biological Meaning)

ğŸ”µ Sky blue â†’ NPM1 / FLT3-ITD / DNMT3A / IDH1/2
(Signaling & epigenetic AML)

ğŸŸ¢ Light green â†’ RUNX1 / SRSF2 / U2AF1 / ASXL1
(Splicing / transcription â€“ secondary AML)

ğŸ”´ Salmon â†’ TP53 / Complex Karyotype
(Adverse-risk AML)

ğŸŸ£ Violet â†’ CEBPA biallelic
(Favorable-risk AML)

Edge Interpretation

Black edges â†’ Strong co-occurrence

Thicker edges â†’ More patients share both mutations

Dense clusters â†’ Biological AML subtypes


âš ï¸ Limitations

Cross-sectional data â†’ associations, not true temporal causality

Thresholding may miss rare subtypes

Simulated dataset used for demonstration



